According to stock market data for the past 24-hours surrounding pharma companies, Astellas Pharma is reportedly observing the worst performance. The stock price for Astellas Pharma has reportedly observed a 4.70% plummet in the past 24-hours. Having observed the plummet, the stock price for Astellas Pharma is now exhibiting a figure worth $16.07 per share. The overall valuation of Astellas Pharma is worth $30.20 billion. The global ranking of Astellas Pharma among the pharma companies in terms of valuation is 32.
The company following the same trend as Astellas Pharma is Otsuka Holdings. The stock price for Otsuka Holdings has reportedly observed a 3.15% plummet in the past 24-hours. Having observed the plummet, the stock price for Otsuka Holdings is now exhibiting a figure worth $34.27 per share. The overall valuation of Otsuka Holdings is worth $18.58 billion. The global ranking of Otsuka Holdings among the pharma companies in terms of valuation is 40.
The company following the same trend as Otsuka Holdings is WuXi Biologics. The stock price for WuXi Biologics has reportedly observed a 2.17% plummet in the past 24-hours. Having observed the plummet, the stock price for WuXi Biologics is now exhibiting a figure worth $19.16 per share. The overall valuation of WuXi Biologics is worth $40.44 billion. The global ranking of WuXi Biologics among the pharma companies in terms of valuation is 29.
The company following the same trend as WuXi Biologics is WuXi AppTec. The stock price for WuXi AppTec has reportedly observed a 1.84% plummet in the past 24-hours. Having observed the plummet, the stock price for WuXi AppTec is now exhibiting a figure worth $13.68 per share. The overall valuation of WuXi AppTec is worth $47.52 billion. The global ranking of WuXi AppTec among the pharma companies in terms of valuation is 25.
The company following the same trend as WuXi AppTec is HUTCHMED. The stock price for HUTCHMED has reportedly observed a 1.84% plummet in the past 24-hours. Having observed the plummet, the stock price for HUTCHMED is now exhibiting a figure worth $25.03 per share. The overall valuation of HUTCHMED is worth $4.48 billion. The global ranking of HUTCHMED among the pharma companies in terms of valuation is 88.
The company following the same trend as HUTCHMED is Sumitomo Dainippon Pharma. The stock price for Sumitomo Dainippon Pharma has reportedly observed a 1.25% plummet in the past 24-hours. Having observed the plummet, the stock price for Sumitomo Dainippon Pharma is now exhibiting a figure worth $10.90 per share. The overall valuation of Sumitomo Dainippon Pharma is worth $4.32 billion. The global ranking of Sumitomo Dainippon Pharma among the pharma companies in terms of valuation is 92.
